Coupling physical exercise with dietary glucose supplement for treating cognitive impairment in schizophrenia: A theoretical model and future directions

Early Intervention in Psychiatry

Volumn 8, Issue 3, 2014, Pages 209-220

  Li, Yuet Keung ^a   Hui, Christy Lai Ming ^a   Lee, Edwin Ho Ming ^a   Chang, Wing Chung ^a   Chan, Sherry Kit Wa ^a   Leung, Chung Ming ^a   Chen, Eric Yu Hai ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cognitive impairment; Exercise; Glucose supplement; Schizophrenia

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUCOSE; INSULIN; NEUROTRANSMITTER; SOMATOMEDIN C;

BRAIN; COGNITION; COGNITIVE DEFECT; DIET SUPPLEMENTATION; DOWN REGULATION; ENERGY RESOURCE; EXERCISE; GLUCOSE INTAKE; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; THEORETICAL MODEL; UPREGULATION; BIOLOGICAL MODEL; COGNITION DISORDERS; COMPLICATION; DIET THERAPY; KINESIOTHERAPY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGY;

COGNITION DISORDERS; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; EXERCISE THERAPY; GLUCOSE; HUMANS; INSULIN RESISTANCE; MODELS, BIOLOGICAL; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84904756814     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12109     Document Type: Review

References (156)

1. O'Carroll R. Cognitive impairment in schizophrenia. Adv Psychiatr Treat 2000; 6: 161-168.
2. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr Res 2005; 74: 15-26.
3. Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998; 24: 425-435.
4. Lencz T, Smith CW, McLaughlin D etal. Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 2006; 59: 863-871.
5. Pukrop R, Ruhrmann S, Schultze-Lutter F, Bechdolf A, Brockhaus-Dumke A, Klosterkotter J. Neurocognitive indicators for a conversion to psychosis: comparison of patients in a potentially initial prodromal state who did or did not convert to a psychosis. Schizophr Res 2007; 92: 116-125.
6. Simon AE, Cattapan-Ludewig K, Zmilacher S etal. Cognitive functioning in the schizophrenia prodrome. Schizophr Bull 2007; 33: 761-771.
7. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006; 67: e12.
8. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201-222.
9. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999; 25: 233-255.
10. Medalia A, Choi J. Cognitive remediation in schizophrenia. Neuropsychol Rev 2009; 19: 353-364.
11. McGurk SR, Twamley EW, Sitzer DI, McHugo GJ, Mueser KT. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164: 1791-1802.
12. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry 2011; 168: 472-485.
13. Dickinson D, Harvey PD. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr Bull 2009; 35: 403-414.
14. Thakore JH. Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 2004; 47: S76-79.
15. Bruehl H, Sweat V, Hassenstab J, Polyakov V, Convit A. Cognitive impairment in nondiabetic middle-aged and older adults is associated with insulin resistance. J Clin Exp Neuropsychol 2010; 32: 487-493.
16. Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995; 38: 1096-1102.
17. Young SE, Mainous AG, 3rd, Carnemolla M. Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 2006; 29: 2688-2693.
18. Gold SM, Dziobek I, Sweat V etal. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007; 50: 711-719.
19. Gregg EW, Yaffe K, Cauley JA etal. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000; 160: 174-180.
20. Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64: 570-575.
21. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999; 16: 93-112.
22. Cholerton B, Baker LD, Craft S. Insulin resistance and pathological brain ageing. Diabet Med 2011; 28: 1463-1475.
23. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-178.
24. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 2000; 49: 1525-1533.
25. Kern W, Benedict C, Schultes B etal. Low cerebrospinal fluid insulin levels in obese humans. Diabetologia 2006; 49: 2790-2792.
26. Schwartz MW, Figlewicz DF, Kahn SE, Baskin DG, Greenwood MR, Porte D, Jr. Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides 1990; 11: 467-472.
27. McEwen BS, Reagan LP. Glucose transporter expression in the central nervous system: relationship to synaptic function. Eur J Pharmacol 2004; 490: 13-24.
28. Grillo CA, Piroli GG, Hendry RM, Reagan LP. Insulin-stimulated translocation of GLUT4 to the plasma membrane in rat hippocampus is PI3-kinase dependent. Brain Res 2009; 1296: 35-45.
29. Duelli R, Kuschinsky W. Brain glucose transporters: relationship to local energy demand. News Physiol Sci 2001; 16: 71-76.
30. Lajtha A, Reith MEA. Handbook of Neurochemistry and Molecular Neurobiology: Neural Membranes and Transport, 3rd edn. New York: Springer, 2007.
31. Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. J Intern Med 2007; 262: 173-183.
32. Rask-Madsen C, King GL. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 46-56.
33. Convit A. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 2005; 26 (Suppl 1): 31-35.
34. Park CR. Cognitive effects of insulin in the central nervous system. Neurosci Biobehav Rev 2001; 25: 311-323.
35. Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004; 490: 71-81.
36. Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV. Insulin promotes rapid delivery of N-methyl-D-aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci U S A 2001; 98: 3561-3566.
37. Rothermundt M, Ahn JN, Jorgens S. S100B in schizophrenia: an update. Gen Physiol Biophys 2009; 28 3: F76-81.
38. Steiner J, Walter M, Guest P etal. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 2010; 15: 3-4.
39. Schroeter ML, Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009; 14: 235-237.
40. Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006; 51: 382-386.
41. Dasgupta A, Singh OP, Rout JK, Saha T, Mandal S. Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1202-1207.
42. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289.
43. Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007; 24: 481-485.
44. Venkatasubramanian G, Chittiprol S, Neelakantachar N etal. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007; 164: 1557-1560.
45. Bushe C, Holt R. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 2004; 47: S67-71.
46. Fernandez-Egea E, Bernardo M, Parellada E etal. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 2008; 103: 110-113.
47. Fernandez-Egea E, Miller B, Bernardo M, Donner T, Kirkpatrick B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res 2008; 98: 302-306.
48. Thakore JH. Metabolic syndrome and schizophrenia. Br J Psychiatry 2005; 186: 455-456.
49. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Shetty T, Gangadhar BN. Effect of antipsychotic treatment on insulin-like growth factor-1 and cortisol in schizophrenia: a longitudinal study. Schizophr Res 2010; 119: 131-137.
50. Holt RI, Simpson HL, Sonksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med 2003; 20: 3-15.
51. Torres-Aleman I. Serum growth factors and neuroprotective surveillance: focus on IGF-1. Mol Neurobiol 2000; 21: 153-160.
52. Sonntag WE, Ramsey M, Carter CS. Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Res Rev 2005; 4: 195-212.
53. van Dam PS, Aleman A, de Vries WR etal. Growth hormone, insulin-like growth factor I and cognitive function in adults. Growth Horm IGF Res 2000; 10 (Suppl B): S69-73.
54. Gunnell D, Holly JM. Do insulin-like growth factors underlie associations of birth complications, fetal and pre-adult growth with schizophrenia? Schizophr Res 2004; 67: 309-311.
55. Schmitt A, Leonardi-Essmann F, Durrenberger PF etal. Regulation of immune-modulatory genes in left superior temporal cortex of schizophrenia patients: a genome-wide microarray study. World J Biol Psychiatry 2011; 12: 201-215.
56. Sainz J, Mata I, Barrera J etal. Inflammatory and immune response genes have significantly altered expression in schizophrenia. Mol Psychiatry 2013; 18: 1056-1057.
57. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E. Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry 2007; 7: 46.
58. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 2007; 62: 711-721.
59. Fawzi MH, Fawzi MM, Fawzi MM, Said NS. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 2011; 190: 91-97.
60. Fernandez-Egea E, Bernardo M, Donner T etal. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry 2009; 194: 434-438.
61. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008; 63: 801-808.
62. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007; 149: 267-271.
63. Dik MG, Jonker C, Comijs HC etal. Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care 2007; 30: 2655-2660.
64. Schram MT, Euser SM, de Craen AJ etal. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007; 55: 708-716.
65. Yaffe K, Kanaya A, Lindquist K etal. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004; 292: 2237-2242.
66. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
67. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008; 582: 97-105.
68. Fan X, Goff DC, Henderson DC. Inflammation and schizophrenia. Expert Rev Neurother 2007; 7: 789-796.
69. Barbieri M, Ferrucci L, Ragno E etal. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab 2003; 284: E481-487.
70. De Benedetti F, Alonzi T, Moretta A etal. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99: 643-650.
71. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22 (Suppl 3): C10-13.
72. Coodin S. Body mass index in persons with schizophrenia. Can J Psychiatry 2001; 46: 549-555.
73. Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002; 26: 137-141.
74. Friedman JI, Wallenstein S, Moshier E etal. The effects of hypertension and body mass index on cognition in schizophrenia. Am J Psychiatry 2010; 167: 1232-1239.
75. Kamijo K, Khan NA, Pontifex MB etal. The relation of adiposity to cognitive control and scholastic achievement in preadolescent children. Obesity (Silver Spring) 2012; 20: 2406-2411.
76. Sabia S, Kivimaki M, Shipley MJ, Marmot MG, Singh-Manoux A. Body mass index over the adult life course and cognition in late midlife: the Whitehall II Cohort Study. Am J Clin Nutr 2009; 89: 601-607.
77. Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther 2004; 26: 1936-1946.
78. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 (Suppl 1): 1-93.
79. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007; 32: 289-297.
80. Hillman CH, Erickson KI, Kramer AF. Be smart, exercise your heart: exercise effects on brain and cognition. Nat Rev Neurosci 2008; 9: 58-65.
81. Sibley BA, Etnier JL. The relationship between physical activity and cognition in children: a meta-analysis. Pediatr Exerc Sci 2003; 15: 243-256.
82. Smith PJ, Blumenthal JA, Hoffman BM etal. Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. Psychosom Med 2010; 72: 239-252.
83. Erickson KI, Kramer AF. Aerobic exercise effects on cognitive and neural plasticity in older adults. Br J Sports Med 2009; 43: 22-24.
84. Osborn DP, Nazareth I, King MB. Physical activity, dietary habits and coronary heart disease risk factor knowledge amongst people with severe mental illness: a cross sectional comparative study in primary care. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 787-793.
85. Roick C, Fritz-Wieacker A, Matschinger H etal. Health habits of patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2007; 42: 268-276.
86. Pajonk FG, Wobrock T, Gruber O etal. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 2010; 67: 133-143.
87. Scheewe TW, Backx FJ, Takken T etal. Exercise therapy improves mental and physical health in schizophrenia: a randomised controlled trial. Acta Psychiatr Scand 2013; 127: 464-473.
88. Miller DL, Weinstein AM, Erickson KI. Structural plasticity induced by physical exercise. In: Boecker H, Hillman CH, Scheef L, Strüder HK, eds. Functional Neuroimaging in Exercise and Sport Sciences. New York: Springer, 2012; 397-415.
89. Angelucci F, Brene S, Mathe AA. BDNF in schizophrenia, depression and corresponding animal models. Mol Psychiatry 2005; 10: 345-352.
90. Lista I, Sorrentino G. Biological mechanisms of physical activity in preventing cognitive decline. Cell Mol Neurobiol 2010; 30: 493-503.
91. Gomes RJ, de Oliveira CA, Ribeiro C etal. Effects of exercise training on hippocampus concentrations of insulin and IGF-1 in diabetic rats. Hippocampus 2009; 19: 981-987.
92. Griffin EW, Bechara RG, Birch AM, Kelly AM. Exercise enhances hippocampal-dependent learning in the rat: evidence for a BDNF-related mechanism. Hippocampus 2009; 19: 973-980.
93. Rasmussen P, Brassard P, Adser H etal. Evidence for a release of brain-derived neurotrophic factor from the brain during exercise. Exp Physiol 2009; 94: 1062-1069.
94. Griffin EW, Mullally S, Foley C, Warmington SA, O'Mara SM, Kelly AM. Aerobic exercise improves hippocampal function and increases BDNF in the serum of young adult males. Physiol Behav 2011; 104: 934-941.
95. Kraemer RR, Durand RJ, Acevedo EO etal. Rigorous running increases growth hormone and insulin-like growth factor-I without altering ghrelin. Exp Biol Med (Maywood) 2004; 229: 240-246.
96. Nofuji Y, Suwa M, Sasaki H, Ichimiya A, Nishichi R, Kumagai S. Different circulating brain-derived neurotrophic factor responses to acute exercise between physically active and sedentary subjects. J Sports Sci Med 2012; 11: 83-88.
97. Rojas Vega S, Knicker A, Hollmann W, Bloch W, Struder HK. Effect of resistance exercise on serum levels of growth factors in humans. Horm Metab Res 2010; 42: 982-986.
98. Seifert T, Brassard P, Wissenberg M etal. Endurance training enhances BDNF release from the human brain. Am J Physiol Regul Integr Comp Physiol 2010; 298: R372-377.
99. Berchtold NC, Castello N, Cotman CW. Exercise and time-dependent benefits to learning and memory. Neuroscience 2010; 167: 588-597.
100. Ding Q, Vaynman S, Akhavan M, Ying Z, Gomez-Pinilla F. Insulin-like growth factor I interfaces with brain-derived neurotrophic factor-mediated synaptic plasticity to modulate aspects of exercise-induced cognitive function. Neuroscience 2006; 140: 823-833.
101. Carro E, Trejo JL, Busiguina S, Torres-Aleman I. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci 2001; 21: 5678-5684.
102. Frosig C, Richter EA. Improved insulin sensitivity after exercise: focus on insulin signaling. Obesity (Silver Spring) 2009; 17 (Suppl 3): S15-20.
103. Chibalin AV, Yu M, Ryder JW etal. Exercise-induced changes in expression and activity of proteins involved in insulin signal transduction in skeletal muscle: differential effects on insulin-receptor substrates 1 and 2. Proc Natl Acad Sci U S A 2000; 97: 38-43.
104. Christ CY, Hunt D, Hancock J, Garcia-Macedo R, Mandarino LJ, Ivy JL. Exercise training improves muscle insulin resistance but not insulin receptor signaling in obese Zucker rats. J Appl Physiol 2002; 92: 736-744.
105. Wheatley CM, Rattigan S, Richards SM, Barrett EJ, Clark MG. Skeletal muscle contraction stimulates capillary recruitment and glucose uptake in insulin-resistant obese Zucker rats. Am J Physiol Endocrinol Metab 2004; 287: E804-809.
106. Hussey SE, McGee SL, Garnham A, McConell GK, Hargreaves M. Exercise increases skeletal muscle GLUT4 gene expression in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14: 768-771.
107. Kennedy JW, Hirshman MF, Gervino EV etal. Acute exercise induces GLUT4 translocation in skeletal muscle of normal human subjects and subjects with type 2 diabetes. Diabetes 1999; 48: 1192-1197.
108. Kirwan JP, del Aguila LF, Hernandez JM etal. Regular exercise enhances insulin activation of IRS-1-associated PI3-kinase in human skeletal muscle. J Appl Physiol 2000; 88: 797-803.
109. Christ-Roberts CY, Pratipanawatr T, Pratipanawatr W etal. Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism 2004; 53: 1233-1242.
110. Mathur N, Pedersen BK. Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm 2008; 2008: Article ID 109502, 6 pages.
111. Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK. Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports 2007; 17: 580-587.
112. Ford ES. Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology 2002; 13: 561-568.
113. Lakka TA, Lakka HM, Rankinen T etal. Effect of exercise training on plasma levels of C-reactive protein in healthy adults: the HERITAGE Family Study. Eur Heart J 2005; 26: 2018-2025.
114. Nicklas BJ, Hsu FC, Brinkley TJ etal. Exercise training and plasma C-reactive protein and interleukin-6 in elderly people. J Am Geriatr Soc 2008; 56: 2045-2052.
115. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154-1162.
116. Ostrowski K, Rohde T, Asp S, Schjerling P, Pedersen BK. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 1999; 515 (Pt 1): 287-291.
117. Sloan RP, Shapiro PA, Demeersman RE etal. Aerobic exercise attenuates inducible TNF production in humans. J Appl Physiol 2007; 103: 1007-1011.
118. Tsukui S, Kanda T, Nara M, Nishino M, Kondo T, Kobayashi I. Moderate-intensity regular exercise decreases serum tumor necrosis factor-alpha and HbA1c levels in healthy women. Int J Obes Relat Metab Disord 2000; 24: 1207-1211.
119. Petersen AM, Pedersen BK. The role of IL-6 in mediating the anti-inflammatory effects of exercise. J Physiol Pharmacol 2006; 57 (Suppl 10): 43-51.
120. Fucetola R, Newcomer JW, Craft S, Melson AK. Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Res 1999; 88: 1-13.
121. Messier C. Glucose improvement of memory: a review. Eur J Pharmacol 2004; 490: 33-57.
122. Newcomer JW, Craft S, Fucetola R etal. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 1999; 25: 321-335.
123. Stone WS, Seidman LJ, Wojcik JD, Green AI. Glucose effects on cognition in schizophrenia. Schizophr Res 2003; 62: 93-103.
124. Smith MA, Riby LM, Eekelen JA, Foster JK. Glucose enhancement of human memory: a comprehensive research review of the glucose memory facilitation effect. Neurosci Biobehav Rev 2011; 35: 770-783.
125. Sunram-Lea SI, Dewhurst SA, Foster JK. The effect of glucose administration on the recollection and familiarity components of recognition memory. Biol Psychol 2008; 77: 69-75.
126. Scholey A, Macpherson H, Sunram-Lea S, Elliott J, Stough C, Kennedy D. Glucose enhancement of recognition memory: differential effects on effortful processing but not aspects of 'remember-know' responses. Neuropharmacology 2013; 64: 544-549.
127. Gold PE. Role of glucose in regulating the brain and cognition. Am J Clin Nutr 1995; 61: 987S-995.
128. Sunram-Lea SI, Owen L, Finnegan Y, Hu H. Dose-response investigation into glucose facilitation of memory performance and mood in healthy young adults. J Psychopharmacol 2011; 25: 1076-1087.
129. McNay EC, Fries TM, Gold PE. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci U S A 2000; 97: 2881-2885.
130. McNay EC, McCarty RC, Gold PE. Fluctuations in brain glucose concentration during behavioral testing: dissociations between brain areas and between brain and blood. Neurobiol Learn Mem 2001; 75: 325-337.
131. Scholey AB, Harper S, Kennedy DO. Cognitive demand and blood glucose. Physiol Behav 2001; 73: 585-592.
132. Stone WS, Seidman LJ. Toward a model of memory enhancement in schizophrenia: glucose administration and hippocampal function. Schizophr Bull 2008; 34: 93-108.
133. Jessen F, Scheef L, Germeshausen L etal. Reduced hippocampal activation during encoding and recognition of words in schizophrenia patients. Am J Psychiatry 2003; 160: 1305-1312.
134. Seidman LJ, Thermenos HW, Poldrack RA etal. Altered brain activation in dorsolateral prefrontal cortex in adolescents and young adults at genetic risk for schizophrenia: an fMRI study of working memory. Schizophr Res 2006; 85: 58-72.
135. Bullock R, Reilly P. Head Injury: Pathophysiology and Management of Severe Closed Injury. London: Chapman & Hall, 1997.
136. Benton D, Parker PY. Breakfast, blood glucose, and cognition. Am J Clin Nutr 1998; 67: 772S-778.
137. Hoyland A, Dye L, Lawton CL. A systematic review of the effect of breakfast on the cognitive performance of children and adolescents. Nutr Res Rev 2009; 22: 220-243.
138. Pollitt E, Mathews R. Breakfast and cognition: an integrative summary. Am J Clin Nutr 1998; 67: 804S-813.
139. Henderson DC, Borba CP, Daley TB etal. Dietary intake profile of patients with schizophrenia. Ann Clin Psychiatry 2006; 18: 99-105.
140. Wenk GL. An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers. Psychopharmacology (Berl) 1989; 99: 431-438.
141. Ragozzino ME, Unick KE, Gold PE. Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci U S A 1996; 93: 4693-4698.
142. Ragozzino ME, Pal SN, Unick K, Stefani MR, Gold PE. Modulation of hippocampal acetylcholine release and spontaneous alternation scores by intrahippocampal glucose injections. J Neurosci 1998; 18: 1595-1601.
143. Ragozzino ME, Gold PE. Glucose injections into the medial septum reverse the effects of intraseptal morphine infusions on hippocampal acetylcholine output and memory. Neuroscience 1995; 68: 981-988.
144. Morris KA, Li S, Bui DD, Gold PE. Glucose attenuates impairments in memory and CREB activation produced by an alpha4beta2 but not an alpha7 nicotinic receptor antagonist. Neuropharmacology 2012; 67C: 233-242.
145. Schwartz MW, Sipols A, Kahn SE etal. Kinetics and specificity of insulin uptake from plasma into cerebrospinal fluid. Am J Physiol 1990; 259: E378-383.
146. Steffens AB, Scheurink AJ, Porte D, Jr, Woods SC. Penetration of peripheral glucose and insulin into cerebrospinal fluid in rats. Am J Physiol 1988; 255: R200-204.
147. Benedict C, Hallschmid M, Schultes B, Born J, Kern W. Intranasal insulin to improve memory function in humans. Neuroendocrinology 2007; 86: 136-142.
148. Benedict C, Hallschmid M, Hatke A etal. Intranasal insulin improves memory in humans. Psychoneuroendocrinology 2004; 29: 1326-1334.
149. Benedict C, Hallschmid M, Schmitz K etal. Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 2007; 32: 239-243.
150. Kern W, Benedict C, Perras B, Fehm HL, Born J, Hallschmid M. Obese are resistant to the catabolic but not to the cognitive effects of central nervous insulin. Diabetologia 2006; 49 (Suppl. 1): 125.
151. Ghelardini C, Galeotti N, Bartolini A. Influence of potassium channel modulators on cognitive processes in mice. Br J Pharmacol 1998; 123: 1079-1084.
152. Stefani MR, Gold PE. Intrahippocampal infusions of k-atp channel modulators influence spontaneous alternation performance: relationships to acetylcholine release in the hippocampus. J Neurosci 2001; 21: 609-614.
153. Huang CW, Huang CC, Cheng JT, Tsai JJ, Wu SN. Glucose and hippocampal neuronal excitability: role of ATP-sensitive potassium channels. J Neurosci Res 2007; 85: 1468-1477.
154. Rashidy-Pour A. ATP-sensitive potassium channels mediate the effects of a peripheral injection of glucose on memory storage in an inhibitory avoidance task. Behav Brain Res 2001; 126: 43-48.
155. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007; 33: 1120-1130.
156. Sutoo D, Akiyama K. Regulation of brain function by exercise. Neurobiol Dis 2003; 13: 1-14.